03.18.24 -- Reducing Batch-To-Batch Variation In Cell Therapy Manufacturing

Allogeneic therapies leverage donor cells to ensure optimal starting material and ensure patients can receive treatment without delays, helping to improve safety and expand patient access.

Investments in allogeneic cell therapies and process-level advancements to achieve commercial scale are paving the way for streamlined, standardized cell therapy development and manufacturing.

As you search for a supplier best suited to help manufacture your product, prioritize the CDMO with previous plasmid production experience needed to avoid common manufacturing obstacles.

Discover an efficient, data-driven process that employs innovative methods to accelerate the selection of a closure containment system that meets the requirements of the modern regulatory landscape.

Build a reliable, de-risked path to the clinic while avoiding unforeseen costs and compliance-related delays with advice from Suparna Sanyal, Ph.D., Head of Viral Vectors Commercial Development.

Venkata Indurthi, Ph.D., discusses key considerations for RNA synthesis processes and methods, their impact on downstream production, and why different project needs may vary.